Summary Extramammary Paget's disease is a particular form of skin cancer of unknown histogenesis. To look for the genetic defects underlying the pathogenesis of this tumour, we have examined loss of heterozygosity (LOH), p53 and human papillomavirus (HPV) status, and the expression of c-erbB-2 and bcl-2 proteins in 14 cases. Unexpectedly, no LOH was detected at several loci commonly lost in other human cancers (namely 3p, 9p, 9q, 13q, 16q, 17p, and 17q) in 12 tumours examined. Altered p53 protein expression was entirely or mostly negative in all 14 cases. Direct sequencing of exons 5-8 of the p53 gene in eight cases revealed no mutation. Polymerase chain reaction amplification of the Ll gene of human papillomavirus (HPV) did not detect the virus that could inactivate p53 and retinoblastoma tumoursuppressor gene products. As expected, c-erbB-2 proto-oncogene protein was overexpressed in six cases. The expression of bcl-2 was negative in all cases. The results presented in this study suggest that molecular events underlying extramammary Paget's disease differ from those of other common epithelial malignancies and that tumour-suppressor genes located in chromosome regions not examined in this study may be important.
Paget's disease presents as a slowly enlarging reddish patch affecting the nipple, anogenital area or other apocrine glandbearing sites and is characterized histologically by the presence of a population of large neoplastic cells with pale-staining cytoplasm (Paget's cells) within the epidermis. The mammary form of the disease is usually associated with underlying ductal carcinoma and is regarded as an epidermal manifestation of a breast carcinoma, although the precise site of origin and mode of migration of Paget's cells to the epidermis is unclear (Toker, 1961) . The pathogenesis and histogenesis of the extramammary form, by contrast, are far more controversial, because most of the cases have no underlying carcinomas and the origin of Paget's cells is unknown (Hart and Millman, 1977; Jones et al, 1979) . A variety of cell types have been proposed as the progenitors of extramammary Paget's cells, including pluripotential germinative epidermal cells (Murrell Jr and McMullan, 1962; Jones et al, 1979) , and cells of both eccrine and apocrine sweat glands (Demopoulos, 1971 ; Lee et al, 1977; Roth et al, 1977; Mazoujian et al, 1984; Hamm et al, 1986) . Furthermore, extramammary Paget's disease may arise multicentrically within the anogenital area (Gunn and Gallager, 1980) or even in distant anatomical sites known as 'triple' extramammary Paget's disease in which genitalia and both sides of axillae are affected at the same time (Kawatsu and Miki, 1971 al, 1990 ) and c-erbB-2 proto-oncogene products (Keatings et al, 1990; Meissner et al, 1990; Wolber et al, 1991; Nishi et al, 1994) , and altered expression of p53 tumour-suppressor protein (Wienecke et al, 1994; Nakamura et al, 1995) . Because of its particular biological properties, we were interested in examining genetic changes in extramammary Paget's disease.
In human epithelial neoplasms, defects in tumour-suppressor genes are common (Fearon and Vogelstein, 1990; Yokota and Sugimura, 1993) . Although tumour-suppressor genes may be inactivated in a number of different ways, a particularly common mechanism is mutation of one allele followed by loss of the remaining allele (Ponder, 1988) . To look for defects in tumoursuppressor genes underlying extramammary Paget's disease, we performed polymerase chain reaction (PCR)-based microsatellite loss of heterozygosity (LOH) assays for several selected loci that map to chromosome regions harbouring important tumoursuppressor genes such as p53 (Nigro et al, 1989) and retinoblastoma (Rb) (Horowitz et al, 1990) and which are commonly deleted in other human cancers (Ponder, 1988; Yokota and Sugimura, 1993) . Furthermore, the p53 status was examined by immunohistochemistry and direct sequencing of exons 5-8 of the p53 gene.
The presence or integration of human papillomaviruses (HPV) into tumour DNA was also investigated, because the disease mainly affects anogenital skin, where HPV infections are not uncommon (DeVita et al, 1987) , and because E6 and E7 oncoproteins encoded by several types of HPV are known to bind to p53 and Rb proteins and to inactivate their tumour-suppressor function (Dyson et al, 1989; Werness et al, 1990) . Finally, the expression of c-erbB-2 and bcl-2 proto-oncogene products was evaluated by immunohistochemistry. Loss of heterozygosity; 0, no loss of heterozygosity; NI, homozygous; NP, no product; -, not examined. b* positive cells less than 5%; C-erbB-2 immunostaining was recorded as + when more than 80% of Paget's cells showed distinct membrane staining.
MATERIALS AND METHODS Selection of clinical samples
A total of 26 cases of extramammary Paget's disease were initially retrieved from the pathology files of the Department of Dermatology at Kanazawa University Hospital. Fresh-frozen tissues had been stored in eight cases and only paraffin-embedded tissue blocks were available in the remaining 18 cases. After reviewing pathology slides, eight cases in which isolated Paget's cells were present only within the epidermis were excluded because they were unsuitable for microdissection. Paraffinembedded sections (15,m) or frozen sections (6 jm) of the remaining 18 tumours were mounted on to glass slides and microdissected using a fine needle point on an inverted microscope. Tumour DNA was isolated according to standard methods by proteinase K digestion and phenol-chloroform extraction as described previously (Takata et al, 1996) . Control DNA was obtained from either peripheral blood or normal adjacent skin of the corresponding patients. An additional four cases were further eliminated at this stage because of the poor quality of tumour and/or control DNA. The remaining 14 cases were subjected to further genetic and immunohistochemical analyses. The patients comprised 12 men and two women. All the male patients had lesions typical of extramammary Paget's disease on genital skin including scrotum and penis. The female patients had a vulvar or a pubic lesion. None of the cases was associated with underlying genitourinary or gastrointestinal malignancies. Histologically, nine tumours had nests or clusters of Paget's cells invading into the dermis and five patients had histologically documented inguinal lymph node metastases (Table 1) .
Microsatellite-PCR loss of heterozygosity analysis LOH was analysed in 12 cases by PCR amplification of microsatellite polymorphism as described previously (Takata et al, 1996) . Approximately 100 ng of template DNA was amplified with 1 pmol of each oligonucleotide primer, one of which was end-labelled with [32P]ATP, 0.2 mm of each deoxynucleotide and 0.5 unit of Taq DNA polymerase (Promega, Madison, WI) in a final volume of 10,l. The microsatellite oligonucleotide primers used were D3S1293 (3p), D9S171 (9p), D9S197 (9q), D13S155 (13q), D16S413 (16q), D17S796 (17p), and D17S785 (17q), all obtained from Research Genetics (Huntsville, AL, USA). PCR products were separated through 6% acrylamide gels, which were subsequently dried and exposed to Fuji XR films overnight at -80°C. LOH was scored visually by two observers and a significant reduction in the signal intensity of one of two tumour alleles was recorded as LOH.
Direct sequencing of the p53 gene Direct sequencing of the p53 gene was carried out in eight cases in which enough DNA was available. Exons 5-8 of p53 gene were amplified by PCR with standard condition using oligonucleotide primers as previously described (Campbell et al, 1993) . Amplification was confirmed by 1% agarose gel electrophoresis, and the PCR products were purified with a DNA affinity spin column (Wizard PCR Preps, Promega, Madison, WI, USA). All purified samples were directly sequenced by automated sequencing with fluorescently labelled dideoxy chain-terminating nucleotides and Taq DNA polymerase using Dye Terminator Cycle Sequencing Ready Reaction Kit (Perkin Elmer, Foster City, CA, USA). The products were analysed on an Applied Biosystems Model 373A Automated DNA sequencing machine.
Detection of HPV DNA HPV DNA sequences were detected by PCR amplification using a primer pair (HPV-1003 and HPV-1004) for the conserved sequence of the LI gene of (Snijders et al, 1990) , purchased from Maxim Biotech (San Francisco, CA, USA). The PCR mixtures contained tumour DNA, 0.1 mm of each deoxynucleotide and 1 unit of Taq DNA polymerase (Promega, Madison, WI, USA) as well as the primers and 
Immunohistochemistry
Immunohistochemical staining for p53, bcl-2 and C-erbB-2 was performed on 4-im paraffin sections using the biotin-streptavidine-peroxidase method. Before immunostaining for p53 and bcl-2, antigen retrieval was performed by immersing slides in sodium citrate buffer (pH 6.0) and heating for 10 min in a conventional microwave oven. After blocking endogenous peroxidase with 3% hydrogen peroxide in methanol, the sections were incubated with primary antibody at 40C overnight followed by sequential 30-min incubations with biotinylated rabbit anti-mouse immunoglobulins and a streptavidin-biotin-peroxidase complex (Histofine Kit, Nichirei, Tokyo, Japan). Primary antibodies used were anti-p53, D07 (1/100) (Novocastra, Newcastle, UK), anti-bcl-2, Ab-l (1/100) (Oncogene Science, Cambridge, MA, USA) and anti-cerbB-2 (1/40) (Novocastra, Newcastle, UK). Primary antibodies were replaced by phosphate-buffered saline in the negative controls. Diaminobenzidine was used as the peroxidase substrate and the sections were counterstained with methylgreen. Only cases exhibiting distinct membrane staining in more than 80% of Paget's cells were identified as positive for c-erbB-2 overexpression (Barbareschi et al, 1992) .
RESULTS
The results of molecular genetic and immunohistochemical analyses in 14 cases are shown in Figure 2 Immunohistochemical analysis of p53 protein (A) and c-erb-B2 (B) expression in extramammary Paget's disease. Note scattered nuclear staining for p53 protein (case 1) and strong membrane staining for c-erb-B2 (case 3). Scale bar = 50 gm loci (Fig. 1) . Altered p53 protein expression was entirely negative in 11 cases, while the remaining three tumours had occasional nuclear staining in less than 5% of Paget's cells ( Fig. 2A) , although nuclear staining was weak or faint in cases 5 and 11. Direct sequencing of exons 5-8 of the p53 gene in eight cases revealed no mutation. PCR amplification of the HPV LI gene failed to detect HPV DNA in all tumours whereas control HPV-18 DNA and HeLa cell DNA consistently gave specific 550-bp products. Overexpression of c-erbB-2 protein was observed in 6 out of 14 tumours (Fig. 2B) . Expression of bcl-2 was entirely negative in all cases.
DISCUSSION
We selected 12 specimens of extramammary Paget's disease suitable for microdissection and conducted PCR-based microsatellite LOH analyses. The analyses were carried out using seven microsatellite polymorphisms on chromosome arms 3p, 9p, 9q, 13q, 16q, 17p and 17q that are commonly deleted in other malignant epithelial tumours including non-melanoma skin cancers (Ponder, 1988; Yokota and Sugimura, 1993; Quinn et al, 1994) . The three microsatellite markers used in this study, D17S796, D9S171 and D13S155, map to l7pl3, 9p2l and 13ql4 respectively, where known important tumour-suppressor genes p53, p16 and Rb reside (Nigro et al, 1989; Horowitz et al, 1990; Kamb et al, 1994) . In view of the phenotypical similarity of extramammary to mammary Paget's disease, which is essentially a skin manifestation of underlying breast carcinoma (Tocker, 1961) , selected loci included several chromosome regions frequently deleted in breast carcinomas (e.g. 3p, 13q, 16q, 17p and 17q), although chromosomes 1, 6, 8, 11 and 22, which are also frequently lost, were not examined (Devilee and Comelisse, 1994) . The result that no LOH was detected at any of the seven loci commonly lost in a wide range of epithelial tumours in any of the 12 tumours is perhaps surprising. Histological and ultrastructural observations show that Paget's cells are adenocarcinoma cells Jones et al, 1979; Ordonez et al, 1987) and most adenocarcinomas do lose these chromosome arms (Ponder, 1988; Fearon and Vogelstein, 1990; Yokota and Sugimura, 1993) . There are a number of factors that need to be considered in interpreting this result. First, LOH could have been missed because of the presence of contaminating non-tumour cells such as keratinocytes, appendageal epithelia and interstitial cells in tumour samples. However, this seems unlikely because we selected tumours that had large nests of Paget's cells within the epidermis and/or dermis that enabled us to dissect our relatively pure tumour samples (tumour cells more than 70-80%).
We have previously detected multiple LOH in smaller lesions such as actinic keratoses (Rehman et al, 1996) . Second, small deletions are likely to have been missed by the present study, in which only one microsatellite locus for one chromosome arm was examined. Third, the inactivation of tumour-suppressor genes may have occurred by mechanisms other than mutation followed by wildtype allelic loss (Fearon and Vogelstein, 1990) .
To examine for mutations of p53 gene, we initially investigated p53 protein expression by immunohistochemistry. Missense mutations of p53 gene stabilize the protein, thus making it amenable to detection by immunohistochemistry, whereas in normal cells wildtype protein is undetectable (Iggo et al, 1990) . Consistent with a previous study using the same D07 antibody (Kanitakis et al, 1993) , p53 expression was mostly negative in our cases of extramammary Paget's disease, suggesting that the absence of p53 mutations, although nonsense or frameshift mutations would not produce stabilized p53 protein (Greenblatt et al, 1994) . The absence of p53 mutations was further confirmed by direct sequencing of exons 5-8 of the p53 gene in eight cases, all of which showed wild-type sequence. Although recent studies showed that the nearly 20% of mutation of the p53 gene occurred outside exons 5-8 (Greenblatt et al, 1994; Casey et al, 1996) , our results strongly suggest that p53 mutations are not operative in the evolution of extramammary Paget's disease.
The absence of p53 mutations and detectable LOH on chromosome arms 17p and 13q prompted us to investigate the participation of HPV in the pathogenesis of extramammary Paget's disease because this virus is frequently found in anogenital tumours (DeVita et al, 1987) , and because the E6 and E7 oncoproteins encoded by high-risk HPVs (e.g. bind to p53 and Rb proteins respectively and inactivate their growth-inhibitory effects (Dyson et al, 1989; Wemess et al, 1990) . In cervical carcinoma, in which HPV is frequently present, low frequency of both p53 mutation and allelic loss at loci implicated in other common malignancies has been reported (Scheffner et al, 1991; BusbyEarle et al, 1993) . Thus, we looked for HPV DNA in our cases by PCR using consensus primers for HPV LI gene (Snijders et al, 1990) . However, in keeping with the previous report using in situ hybridization (Snow et al, 1992 ), we could not detect HPV genome in any tumours examined. Therefore, the involvement of HPV in the tumorigenesis of extramammary Paget's disease seems unlikely, although there remains a possibility that a virus may play a 'hit and run' role in tumour pathogenesis (Campo et al, 1985) .
Finally, we examined the expression of c-erbB-2 protein, a protooncogene product reported to be overexpressed in a subset of extramammary Paget's disease (Keatings et al, 1990; Meissner et al, 1990; Wolber et al, 1991; Nishi et al, 1994) , and bcl-2 protein, which belongs to a group of proto-oncogenes that prolong the survival of cells by blocking apoptosis (Lu et al, 1996) . As expected, overexpression of c-erbB-2 protein, which reflects c-erbB-2 gene amplification, was observed in 43% of the tumours. The higher prevalence of c-erbB-2 overexpression in our series compared with previous studies (Keatings et al, 1990; Meissner et al, 1990; Wolber et al, 1991; Nishi et al, 1994) may be explained by case selection bias because 9 out of 14 cases investigated in this study were invasive carcinomas, in which c-erbB-2 overexpression is generally more prominent than in in situ lesions (Nishi et al, 1994) . Expression of bcl-2 was entirely negative in all cases, suggesting that activation of bcl-2 proto-oncogene does not play a role.
Unexpectedly, this study did not detect any allelic loss at several selected loci implicated in other common epithelial malignancies including non-melanoma skin cancers and breast carcinoma in extramammary Paget's disease. No mutations of the p53 gene were detected, and the participation of HPV infection, which could alternatively inactivate p53 and Rb tumour suppressor genes by mechanisms other than mutation followed by LOH, was unlikely. These results suggest that the underlying genetic defects in extramammary Paget's disease are different from those in other common epithelial malignancies, and that tumour-suppressor genes located in chromosome regions not examined in this study may be important. It is worth examining LOH patterns in sweat gland carcinomas because of the suspected relationship between extramammary Paget's disease and eccrine or apocrine sweat glands (Demopoulos, 1971; Lee et al, 1977; Roth et al, 1977; Mazoujian et al, 1984; Hamm et al, 1986) . We previously showed isolated LOH at 17q in an eccrine porocarcinoma (Takata et al, 1996) . LOH assays of additional cases of sweat gland carcinomas are now underway in our laboratory. Further molecular genetic studies will provide new insights into the controversial histogenesis and peculiar biological behaviour of this particular skin cancer.
